Status:
COMPLETED
The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients
Lead Sponsor:
National Kidney and Transplant Institute, Philippines
Conditions:
Chronic Kidney Disease
Anemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
This is a prospective observational study on incident peritoneal dialysis patients on the effect of hemoglobin level and vascular reactivity using the generic erythropoietin alpha. The objective of th...
Detailed Description
This is an investigator-initiated study partially subsidized by the Unilab- Biomedis- Biomedis by providing the drug Renogen® 4,000 units/vial, H2 Receptor Blocker and Ferrous Sulfate. The supporting ...
Eligibility Criteria
Inclusion
- Patients aged 18 to 60 years old
- Newly diagnosed ESRD patients started on peritoneal dialysis for less than 3 months not previously on any type of EPO. If previously on a different brand of EPO, patient will have a washout period of 4 weeks.
- Can follow up at NKTI OPD for at least 3 months
- Can take oral iron supplements
Exclusion
- Known allergy to EPO
- With severe illness such as congestive heart failure Class III - IV, acute myocardial infarction, infection within 1 month of starting the study or had a severe hepatic disease.
Key Trial Info
Start Date :
October 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03286712
Start Date
October 1 2015
End Date
May 1 2017
Last Update
September 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Adult Nephrology; National Kidney and Transplant Institute
Quezon City, National Capital Region, Philippines, 1101